Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Boehringer Ingelheim
Moodys
Baxter
Dow

Last Updated: January 27, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ASPIRIN; DIPYRIDAMOLE

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

All Clinical Trials for Aspirin; Dipyridamole

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000463 Post Coronary Artery Bypass Graft (CABG) Study Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1987-04-01 To determine the relative effectiveness of moderate versus more aggressive lipid lowering, and of low dose anticoagulation versus placebo, in delaying saphenous vein coronary bypass graft atherosclerosis and preventing occlusion of saphenous grafts of patients with saphenous vein coronary bypass grafts placed 1 to 11 years previously.
NCT00000496 Platelet Drug Trial in Coronary Disease Progression Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1979-12-01 To determine the effectiveness of the platelet inhibitor drugs dipyridamole and aspirin in reducing the angiographic progression of coronary artery disease over a five-year period and to test the predictive value of the platelet survival half-life in identifying patients with more rapid progression of coronary disease and development of its complications.
NCT00000510 Platelet-Inhibitor Drug Trial in Coronary Angioplasty Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1983-09-01 To determine the effectiveness of dipyridamole and aspirin in prevention of restenosis of the dilated lesion in patients who had undergone percutaneous transluminal coronary angioplasty (PTCA). Secondary aims were to determine the effectiveness of platelet inhibitor therapy in reducing the incidence of coronary events and the severity and incidence of angina.
NCT00000527 Recurrent Carotid Stenosis Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 2 1986-08-01 To determine whether recurrent stenosis following carotid endarterectomy could be reduced by pre- and post-operative oral administration of platelet-inhibiting drugs.
NCT00000527 Recurrent Carotid Stenosis Completed Emory University Phase 2 1986-08-01 To determine whether recurrent stenosis following carotid endarterectomy could be reduced by pre- and post-operative oral administration of platelet-inhibiting drugs.
NCT00129038 Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients Completed Boehringer Ingelheim Phase 4 2004-04-01 The primary objective of this study is to assess whether adding modified-release dipyridamole to aspirin (Asasantin Retard) has measurable effects on markers of platelet function (for example, platelet aggregation) in patients with cardiovascular disease who are known to be resistant to aspirin alone
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Aspirin; Dipyridamole

Condition Name

Condition Name for Aspirin; Dipyridamole
Intervention Trials
Cardiovascular Diseases 4
Stroke 4
Heart Diseases 4
Myocardial Ischemia 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Aspirin; Dipyridamole
Intervention Trials
Cardiovascular Diseases 5
Coronary Artery Disease 4
Stroke 4
Myocardial Ischemia 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Aspirin; Dipyridamole

Trials by Country

Trials by Country for Aspirin; Dipyridamole
Location Trials
United States 48
Canada 9
Italy 5
Australia 4
United Kingdom 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Aspirin; Dipyridamole
Location Trials
Tennessee 2
Oklahoma 2
New York 2
Minnesota 2
Pennsylvania 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Aspirin; Dipyridamole

Clinical Trial Phase

Clinical Trial Phase for Aspirin; Dipyridamole
Clinical Trial Phase Trials
Phase 4 7
Phase 3 7
Phase 2/Phase 3 1
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Aspirin; Dipyridamole
Clinical Trial Phase Trials
Completed 14
Recruiting 4
Terminated 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Aspirin; Dipyridamole

Sponsor Name

Sponsor Name for Aspirin; Dipyridamole
Sponsor Trials
Boehringer Ingelheim 5
National Heart, Lung, and Blood Institute (NHLBI) 4
Yangzhou University 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Aspirin; Dipyridamole
Sponsor Trials
Other 21
Industry 8
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Harvard Business School
Baxter
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.